The role of aY2-adrenoceptors on vascular sympathetic nerve endings in modulating release of the sympathetic neurotransmitter norepinephrine (NE) in humans was examined by measuring the regional rate of appearance of NE in forearm venous plasma (forearm NE spillover [FSO]) in 32 healthy volunteers during intra-arterial infusion of drugs acting at adrenoceptors or directly on vascular smooth muscle. Simultaneous intra-arterial infusions of tracer amounts of [3H]NE were used to calculate the extraction rate of NE in the forearm. Methoxamine or propranolol with epinephrine (PRO+EPI) was used to stimulate a'adrenoceptors, yohimbine was used to inhibit a£adrenoceptors, and sodium nitroprusside (NIP) was used to produce increases in forearm blood flow directly. Sympathetic efferent activity was manipulated by systemic intravenous infusions of NIP or trimethaphan. Yohimbine and NIP increased and PRO+EPI and methoxamine decreased NE FSO, without effects on systemic blood pressure, heart rate, or arterial levels of catechols. Changes in FSO were flow dependent; therefore, the slope of the relation between the changes in FSO and forearm blood flow was used to evaluate the effects of each drug on regional sympathoneural activity. During administration of yohimbine, the mean slope of the relation between the change in estimated FSO and the change in forearm blood flow was about four times that of the mean slope during administration of NIP (F= 6.35 
In the present study of healthy volunteers, forearm blood flow (FBF) was manipulated by intra-arterial infusions of MTX or NIP, and the results were compared with the effects of the drugs acting at a2-adrenoceptors. Some subjects received propranolol with epinephrine (designated PRO+EPI) or yohimbine (YOH) intra-arterially, and the effects on systemic and forearm hemodynamics and on arterial levels of catechols and FSO were assessed. In some subjects, to examine whether the extent of sympathetic outflow influences a-adrenoceptor function, PRO+EPI and YOH were infused before and during systemic intravenous infusions of NIP or trimethaphan (TRI Figure 1A) , and in seven subjects NIP was infused at 5, 15, and 50 ng/kg/min i.a. to increase FBF ( Figure 1B ). Each dose of each drug was given for 8 minutes.
Intra-arterial PRO+EPI was infused to stimulate a-adrenoceptors in 25 subjects ( Figure 1C) . PRO Figure 2 ). To determine if decreased sympathetic nerve traffic would affect the function of a2-adrenoceptors, in seven subjects PRO+EPI and YOH were given, as described above, before and during simultaneous systemic intravenous infusion of TRI at a dose of 1.5 mg/min ( Figure 2 ).
Between infusions, a period of at least 20 minutes was allotted, during which FBF returned to baseline. Arterial blood was drawn before and at the end of each infusion. Venous blood was drawn at the end of each dose. FBF was measured during the last 2 minutes of each dose. When the same drug was given twice (e.g., before and during systemic intravenous infusion of NIP or TRI), at least 1 hour elapsed before the start of the second infusion.
Because each subject served as his own control and since there were several pharmacological manipulations in each study session, the durations of the infusions were limited as much as possible. In a few subjects, blood was drawn at 8 and 15 minutes during infusions of [3H]NE, and no differences in the plasma levels were noted. Therefore, we decided that 8 minutes for each infusion of [3H]NE, including the initial baseline infusion, would be sufficient for the specific purposes of the study. Drug Solutions, Sample Collection, and Assays L-[2,5,6-3H]NE (specific activity, 38.7 Ci/mmol; radiochemical purity, 95%; New England Nuclear, Boston) was diluted in 5% glucose on the morning of each investigation. Blood samples were collected in icechilled, heparinized tubes. Samples were centrifuged at 4°C and 3,500g for 15 minutes, and the plasma was removed and stored at -75°C until assayed.
Catechol Assays
The catechols in aliquots of 1 ml plasma were partially purified by batch alumina extraction, separated using high-pressure liquid chromatography, and quantified by the current produced on exposure of the column effluent to oxidizing and then reducing potentials in series.30 Recovery through the alumina extraction step averaged 70-80% for catecholamines and 45-55% for dopa and dihydroxyphenylglycol (DHPG). Catechol concentrations in each sample were corrected for recovery of an internal standard, N-methyldopamine. Levels of dopa and DHPG were further corrected for differences in recovery of the internal standard and of dopa and DHPG in a mixture of external standards. The limit of detection was about 10 pg/ml for each catechol. 3-2- Figure 7 ). FSO also was increased by YOH to a larger extent during than FSO before NIP infusion (110% versus 58%,p<0.005, Figure 7 ). The slope of the relation between changes in FSO and changes in FBF was unchanged by systemic NIP infusion (F=0.06, p=0.8 by ANCOVA for comparison between slopes, Figure 7) . Systemic (F=0.64, p=0.43 by ANCOVA for comparison between slopes, Figure 8 ). YOH Before and During Systemic TRI Infusion YOH increased FBF slightly more before than during TRI infusion (26% versus 11%, Figure 9 ). The response of FSO also tended to be higher before than during TRI infusion (89% versus 48%). The slope of the relation between changes in FSO and changes in FBF was unchanged during the TRI infusion This technique allowed a distinction between changes in NE release resulting from alterations in presynaptic a2-adrenoceptor activity from changes in NE release resulting from effects mediated by central neural a2-adrenoceptors or reflexive adjustments to direct hemodynamic effects of the drugs. Since none of the intra-arterial infusions, including those of the potent vasodilator NIP and the vasoconstrictors MTX and PRO+EPI, affected systemic blood pressures, heart rate, or arterial levels of catechols, the effects of the drugs administered intra-arterially on regional NE spillover were probably due to local actions in the forearm rather than reflexive adjustments in sympathetic outflow related to central or systemic actions of the drugs.
The FSO was decreased during intra-arterial infusion of PRO+EPI to stimulate a-adrenoceptors and was increased during intra-arterial infusion of the a2-adrenoceptor blocker YOH. Therefore, the results indicated that in the human forearm a2-adrenoceptors on vascular sympathetic nerve endings do modulate release of the sympathetic neurotransmitter.
As expected, intra-arterial administration of PRO+EPI decreased FBF, and intra-arterial infusion of YOH increased FBF. When FBF was decreased by intra-arterial infusion of MTX, FSO decreased, and when FBF was increased by intraarterial infusion of NIP, FSO increased. These findings confirm that regional NE spillover is dependent on regional blood flow.25 To assess the extent to which alterations in regional NE spillover during intra-arterial administration of the PRO+EPI combination and of YOH could be attributed to the concurrent regional flow changes, the slope of the relation between changes in FSO and changes in FBF during administration of PRO+EPI was compared with the slope during administration of MTX, and the slope during ad- (gglkglmln) The present study also examined the possibility that the function of a2-adrenoceptors on sympathetic nerve endings might be altered when sympathetic postganglionic activity is manipulated. Bevan et a131 suggested that high concentrations of NE in the synaptic cleft would desensitize presynaptic a-adrenoceptors. In the present study, when sympathetic activity was stimulated reflexively by systemic intravenous administration of NIP, the slopes of the relations between changes in FSO and changes in FBF during infusion of YOH were unchanged; and the mean slope of the relation between changes in FSO and changes in FBF during YOH infusion was not affected significantly when postganglionic sympathetic activity was blocked by TRI (Figures 8  and 9 ). Therefore, the results suggest that acute alterations in sympathetic outflow do not affect importantly the function of a2-adrenoceptors on sympathetic nerve endings. Consistent with these findings, Szemeredi et a132 found that in conscious rats the effects of clonidine administration on plasma NE levels are similar, with or without reflexive stimulation of sympathetic outflow. Although there was an increase in the slope for the relation between changes in spillover and flow when NIP was coadministered with the PRO+EPI combination, the values for FBF were very low at the highest dose of EPI; therefore, values of FSO were
In conclusion, since intra-arterial infusion of YOH produced much larger increments in FSO than could be attributed to local or systemic hemodynamic effects of the drug, the results support the existence of functional a2-adrenoceptors on vascular sympathetic nerve endings that modulate release of NE in humans. The activity of these receptors does not appear to be augmented during reflexive stimulation of sympathetic outflow, casting doubt on the hypothesis that presynaptic inhibitory a2-adrenoceptors are downregulated in response to increased junctional NE concentrations.
